Insights into direct anticoagulants

Elias Saad, Najib Dally

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


For the past five decades, vitamin K antagonists (VKA) have been the only class of oral anticoagulants available for treating or preventing venous and arterial thromboembolism. Recently, new oral anticoagulants were developed to address significant restrictions regarding the use of VKAs. These drugs act by direct blockade of activated coagulation factor X (FXa) or thrombin. This present mini-review highlights the pharmacological properties of these new anticoagulants, and discusses the supporting evidence for their usage as well as points to potential advantages and disadvantages of using these novel drugs in clinical practice.

Original languageEnglish
Pages (from-to)492-498
Number of pages7
JournalBlood Coagulation and Fibrinolysis
Issue number5
StatePublished - 10 Jul 2015

Bibliographical note

Publisher Copyright:
© 2015 Wolters Kluwer Health, Inc.


  • anticoagulants
  • direct thrombin inhibitors
  • factor Xa inhibitors
  • thromboembolism


Dive into the research topics of 'Insights into direct anticoagulants'. Together they form a unique fingerprint.

Cite this